drugset / Trial / NCT00555204

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

NCT00555204

Phase 2 Terminated 337 enrolled Abbott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.

Timeline

Start
2007-11
Primary completion
2009-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pozanicline Small molecule 5 mg
Subject Pozanicline Small molecule 10 mg
Subject Pozanicline Small molecule 15 mg
Subject Pozanicline Small molecule 20 mg
Subject Pozanicline Small molecule 30 mg
Subject Pozanicline Small molecule 35 mg

Indications